Laekna Pharmaceuticals-B (02105) issued a total of 273,000 shares to satisfy the vesting of RSUs granted under the 2024 Share Award Scheme.

Lai Kai Pharma-B (02105) announced that on September 8, 2026, the company will issue a total of 273,000 ordinary shares to satisfy the vesting of RSUs granted under the 2024 Share Incentive Plan.

Zhitong FinanceSep 8 20:18

Shares of Laekna-B rose in early trading as the first patient was enrolled in the Phase I clinical trial of LAE118.

Laekna Pharmaceuticals-B (02105) rose over 9% in early trading. As of press time, the stock was up 9.37% to HK$7.005, with a turnover of HK$10.244 million.

Zhitong FinanceSep 1 09:46

Laekna Advances Obesity Drug LAE102 With Positive Phase I Data

TipRanksAug 25 23:15

Laikaimedicine-B (02105) announced its interim results, with other income reaching RMB 25.962 million, a year-on-year increase of 30.41%.

Laekna Therapeutics-B (02105) announced its interim results for the six months ended June 30, 2026. The Group recorded other income of RMB 25.962 million (RMB hereinafter), a year-on-year increase of 30.41%; research and development expenses amounted to RMB 97 million, a year-on-year decrease of 7.79%; and the loss for the period was RMB 2.549 million, a year-on-year decrease of 98.03%.

Zhitong FinanceAug 25 23:03

LAEKNA-B: INTERIM RESULTS ANNOUNCEMENTFOR SIX MONTHS ENDED JUNE 30, 2026

HKEXAug 25 22:47

Vaccine ETFs from China Merchants Fund and Harvest Fund hit limit up! The world's first mRNA influenza vaccine receives FDA approval for market launch.

Vaccine stocks surged, with Baike Biologics, Walvax Biotechnology, CanSinoBIO, Kanghua Biological, and Zhifei Biological hitting the 20% daily limit up. This rally drove the China Merchants Vaccine ETF and Harvest Vaccine ETF to their daily limits as well. The Fullgoal Vaccine ETF and Guotai Vaccine ETF rose more than 8%, while the Penghua Vaccine ETF gained over 7%. These vaccine ETFs track the CNI Vaccine & Biotech Index, with major constituents including Fosun Pharma, Changchun High-Tech, Walvax Biotechnology, Joinn Laboratories, Zhifei Biological, Hualan Bioengineering, Livzon Group, Wantai Bio-Pharm, Liaoning Chengda, and Wuxi Apptec. On the news front, Moderna and Merck & Co announced on Wednesday that their collaborative mRNA personalized cancer

Gelonghui FinanceAug 20 10:22